Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 280 results for coronavirus

  1. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

    This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.

  2. Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)

    Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.

  3. What is the effectiveness of awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher oxygen needs?

    awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher...

  4. Indoor air quality at home

    In development Reference number: GID-QS10113 Expected publication date: TBC

  5. What pathophysiological mechanism(s) underlie the most common presentations of post-COVID-19 syndrome? For example, generalised fatigue, breathlessness, and “brain fog”?

    pathophysiological mechanism(s) underlie the most common presentations of post-COVID-19 syndrome? For example, generalised...

  6. What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors for VTE?

    pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors...

  7. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) (NG200)

    This guideline has been withdrawn. VITT is associated with the COVID-19 Vaccine AstraZeneca, which is no longer available from the NHS. For people with COVID-19, see our guideline on managing COVID-19.

  8. Vaccine uptake in the general population (NG218)

    This guideline aims to increase the uptake of all vaccines provided on the NHS routine UK immunisation schedule by everyone who is eligible. It supports the aims of the NHS Long Term Plan , which includes actions to improve immunisation coverage by GPs (including the changes to vaccinations and immunisations detailed in the 2021/2022 and 2022/23 GP contracts ) and support a narrowing of health inequalities.

  9. Perioperative care in adults

    In development Reference number: GID-QS10094 Expected publication date:  01 July 2026

  10. Does a multidisciplinary team agreed approach to weaning from continuous positive airway pressure improve weaning times and result in stopping continuous positive airway pressure for people with COVID-19 and acute respiratory failure?

    result in stopping continuous positive airway pressure for people with COVID-19 and acute respiratory failure? Any...

  11. Mental wellbeing at work (NG212)

    This guideline covers how to create the right conditions for mental wellbeing at work. It aims to promote a supportive and inclusive work environment, including training and support for managers and helping people who have or are at risk of poor mental health.

  12. What are the views, preferences and experiences of people with COVID-19-associated pulmonary aspergillosis (CAPA), and their families or carers, on:• available tests for diagnosing CAPA• available treatments for CAPA?

    Question What are the views, preferences and experiences of people with COVID-19-associated pulmonary aspergillosis (CAPA),...

  13. What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs) compared with a standard prophylactic dose for venous thromboembolism (VTE) prophylaxis in young people under 18 years with COVID-19?

    venous thromboembolism (VTE) prophylaxis in young people under 18 years with COVID-19? Any explanatory notes(if applicable)...

  14. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.